anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Great advancements have been made in the management of lymphedema of the extremities with lymphatic surgery. However, lymphedema of other regions, including head and neck, has remained neglected. Recent discovery of lymphatic system in the brain and the communication between intracranial and paracranial lymphatic systems has drawn attention to the head and neck lymphatics. Lymphedema of the head and neck region can result from inherent abnormality of the lymphatic system (primary) or be caused by accidental or iatrogenic injury to lymphatics (secondary). The head and neck contain a large network of lymphatic tissue. They may be affected by direct tumor infiltration, surgical resection of tumors and surrounding cancer tissue, and/or radiotherapy. Proper screening and counseling of patients before facial aesthetic procedures may avoid managing the distress of lymphedema postprocedure. Progression of head and neck lymphedema (HNL) can lead to chronic inflammatory, fibrosclerotic, and fibrofatty deposition, resulting in permanent deformity and disability. Patients may experience functional impairment, including skin changes, pain, range of motion limitations, contracture, dysphagia, dysarthria, dyspnea, and trismus, all leading to reduced quality of life. Despite these known disabilities, HNL is underdiagnosed due to a lack of awareness about this entity and of tools available for measuring internal or external swelling. The authors' article comprehensively reviews the current diagnostic methods and management strategies and what lies ahead.
The invention discloses a dimemorfan phosphate capsule composition and a preparing method thereof. The composition comprises, by weight, 7.2-10.0% of dimemorfan phosphate, 80.6-86.8% of filler, 3.6-6.1% of disintegrating agent, 0.7-1.0% of adhesive, 1.1-1.8% of flow aid and 0.6-0.8% of lubricant. The compatibility between the main drug and auxiliary materials of the composition is high. The capsules have the advantages of being definite in treatment effect, high in dissolution rate, easy to absorb and the like. The preparing process is simple, stable and high in reproducibility. The prepared product is stable and reliable. Industrialized production of dimemorfan phosphate capsules is realized. The development and successful industrialization of the dimemorfan phosphate capsules provide a more effective and safer drug choice for patients suffering from coughing and fill in the gap of the product in China, high economic benefits can be obtained, and enormous social benefits can be generated.
The invention discloses a kind of preparation processes of Calcium Chloride and Sodium Bromide Injection, it has follow steps: 1. being heated to boiling by a small amount of water for injection, and the calcium chloride of recipe quantity is first put under fluidized state, put into the sodium bromide and stirring and dissolving of recipe quantity after stirring and dissolving under fluidized state again；2. first being boiled, being returned with the salt acid for adjusting pH of 0.5N to 2.0~3.0, filter；3. adjusting pH to 7.5~8.5 with the sodium hydroxide of 0.5N again, boil, return, filters；4. add to the full amount of water for injection 70%~85%, medicinal carbon is added, boils, returns, it is cooling, with the salt acid for adjusting pH of 0.1N to 4.6~4.8；5. adding to the full amount of water for injection；6. according to prescription specification encapsulating, 121 DEG C of sterilizing 15min.Method of the invention is able to solve existing Calcium Chloride and Sodium Bromide Injection and the problem of visible foreign matters easily occurs, especially has better stability in high temperature or Frozen-thawed cycled.
Gilenya represents the most recent advance in MS disease-modification therapy (DMT) and shows promise for neuroprotection, a feature relevant to the progressive neurologic damage associated with the disease. Cognitive impairment accompanies MS in 40-60% of cases and when present, additional symptomatic treatment combined with DMT is required. To date no symptomatic pharmacologic therapy has shown a consistent benefit on MS associated cognitive dysfunction. However, non-pharmacologic approaches show promise. With recent technical and scientific advances, cognitive training is rapidly evolving to become the most effective intervention for the cognitive impairments associated with a wide range of neurological conditions. However, these training programs have not yet been studied in MS.

This study will be a randomized open-label clinical pilot trial to compare a plasticity-based and adaptive cognitive remediation (PACR) program to an active control (ordinary computer games) in 20 adults with multiple sclerosis (MS) starting Gilenya therapy. Primary outcome measures will be used as preliminary indicators of effect, with improvements on program task-related measures and changes in cognitive measures. Secondary outcome measures will determine the feasibility of the use of these programs in patients with MS, as indicated by compliance and patient-reported experience.
Remission induction therapy will be administrated as ATRA 25/mg/m2/day for 28 continuous days without interruption if APL is suspected. ATO 0.3mg/kg/day for days 1-5 (5 doses) and then 0.25 mg/kg/day every other day twice a week for the next 3 weeks (6 doses).
Direct patient injection of potassium chloride at this concentration may be instantaneously fatal. Potassium Chloride for Injection Concentrate must be diluted before administration. Fatal cardiac arrhythmia and cardiac arrest have occurred when potassium chloride was administered in an undiluted form.

To avoid potassium intoxication, do not infuse these solutions rapidly. In patients with renal insufficiency, administration of potassium chloride may cause potassium intoxication and life-threatening hyperkalemia.The administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.

The risk of dilutional states is inversely proportional to the electrolyte concentration. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentration. In patients with diminished renal function, administration of solutions containing potassium ions may result in potassium retention.

This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
OBJECTIVES: Dietary inflammatory index (DII) is utilized to determine the inflammatory effects of nutrients and foods on various diseases. Inflammation is a potential risk factor for anemia. We hypothesize that pro-inflammatory diets boost the incidence of anemia, as indicated by high DII.
METHODS: 41, 360 Americans were included in this study from the U.S. National Health and Nutrition Survey (NHANES) from 2003-2018. Multivariable logistic regression models were employed to examine the association between DII and anemia.
RESULTS: After adjustment for all the covariates, the odds ratios (ORs) (95% CI) between the risk of anemia and DII across tertile 3 were 1.2556 (95% CI 1.0621, 1.4843; P = 0.0077), and the trend test was statistically significant (P for trend = 0.009). Furthermore, in the subgroup analysis stratified by gender. The ORs (95% CI) between the risk of anemia and DII across tertile 2 and 3 were 1.8071 (95% CI 1.1754, 2.7783; P = 0.0070) and 2.1591 (95% CI 1.4009, 3.3278; P = 0.0005) in men after multivariable adjustment. However, in women, this association was only significantly different (P < 0.05) across tertile 3 in the crude model. In the subgroup analysis stratified by race, this association was significant (P < 0.05) between the risk of anemia and DII for Non-Hispanic Whites/Blacks after adjustment.
DISCUSSION: Together, anemia was significantly associated with DII using logistic regression. In stratified analyses, higher DII scores were linked to an increased incidence of anemia in men, while no association was found in women after adjustment. Additionally, anemia may be associated with greater pro-inflammatory diets in Non-Hispanic Whites/Blacks.
CONCLUSION: In the present study, we evaluate the potential relationship between DII and anemia using data from NHANES. This cross-sectional study confirmed the hypothesis that the higher DII was significantly associated with a higher risk of anemia in the U.S. population.
Hypotensive Effects – Postural hypotension, simple tachycardia, momentary fainting and dizziness may occur rarely, after the first oral dose. Usually recovery is spontaneous and symptoms disappear within ½ to 2 hours. Occasionally, these effects may be more severe and prolonged, producing a shock-like condition.

To control hypotension, place patient in head–low position with legs raised. If a vasoconstrictor is required, norepinephrine and phenylephrine are the most suitable. Other pressor agents, including epinephrine, should not be used as they may cause a paradoxical further lowering of blood pressure.

EKG Changes – particularly nonspecific, usually reversible Q and T wave distortions - have been observed in some patients receiving phenothiazine tranquilizers, including chlorpromazine.

Note: Sudden death, apparently due to cardiac arrest, has been reported.
A method for the production of an extract of Phyllanthus wherein (a) Phyllanthus components are extracted with an ethanol/water mixture of 5-85% m/m to which a heavy-metal chelator is added at a concentration of 0.001-3% m/m; (b) the primary extract obtained in step (a) is contacted and concentrated with (ba) Indian Sterculia gum at a final concentration of 0.5-5.0% mm relative to the sum of the extractive substances or (bb) one or more polymers and impendable and/or soluble substance(s); and (c) the concentrated extract obtained in step (b) is dried. The method according to the invention leads to particularly high yield of pharmaceutically effective plant ingredients and is thus of particular interest for therapeutic applications. In a preferred embodiment of the invention the method according to the invention includes a filtration step of the primary extract. It is further preferred that a lipoid is added during the extraction method. The Phyllanthus  Phyllanthus amarus  is preferred. Moreover, the invention relates to pharmaceutical compositions containing the extracts obtained by the method of the invention
Each session will consist of the G-EO System training and stretching exercises. Total net treatment time/session: 50 minutes. Physiotherapists will alter constraints to grade tasks according to patient ability. The training complexity will be increased, as the patient will improve in performance (i.e. increasing gait speed, reducing body weight support, increasing the number of repetition). Heart rate during training sessions will be monitored using a Polar V800. Heart rate will not exceed the threshold of 120 bpm.
1. Technical Result Simplification of chemical technology.           2. Essence A method for preparation of the compounds of the formula (IA) and (IB)   which comprises interaction of the compounds of the formula (IIA) and (IIB) (provided in the specification) with OR, wherein R is CH2CH3 in the case of preparation of the compound (IA) and R is CH2CH2CH3 in the case of preparation of the compound (IB), and also the method for preparation of transient compounds.          3. Field of Application Chemical industry.
The invention provides gelatin and rose oral liquid used for relieving dormancy and removing chloasma, which relates to the field of health care products. In a woman group, the generation of the chloasma has close relation with poor dormancy quality and unbalanced body functions, but no effective drug can treat the chloasma since a long time ago. The invention provides the gelatin and rose oral liquid from the view of traditional Chinese medicine, which comprises the following compositions: angelica, wolfberry fruit, wild jujube, shizandra, donkey-hide gelatin and rose, and flavoring agent and preservative agent as auxiliary materials. The oral liquid has the functions of calming the nerves, tonifying qi, relieving dormancy, beautifying, protecting the skin and removing chloasma. Tests for dormancy improvement and chloasma removal approve that total effective rates for the two tests are 74.7 percent and 76.36 percent respectively. The gelatin and rose oral liquid also has the advantages of convenient use, low price, no toxic and side effects, easy acceptance by patients and convenient popularization.
The present invention relates to a traditional Chinese medicine preparation for treating psoriasis and a preparation method thereof. The traditional Chinese medicine preparation is prepared after the treatment of impurity removal, purification, drying, grinding, uniform mixing and sterilization. The traditional Chinese medicine preparation of the present invention has the functions of adjusting immunity, cooling blood, nourishing blood, dispelling wind, removing blood stasis, removing toxicity, strengthening the body surface resistance, abating rash, relieving itching, etc. The traditional Chinese medicine preparation can treat psoriasis, neurodermatitis, eczema, prurigo nodularis, etc. The traditional Chinese medicine preparation is preferably prepared into capsules; compared with common decoction, medicinal powder and pills, the present invention is easy to take and removes the difficulties of bitter mouth feeling of the medicine, large quantity and difficult administration. The traditional Chinese medicine preparation for treating psoriasis is sterilized by the radiation of cobalt<60>, so the sanitation is absolutely reliable.
FIELD: medicine. ^ SUBSTANCE: invention relates to field of medicine, in particular, to ophthalmology. Therapeutic medication for treatment of corneal-conjunctival disturbance contains eprosartan or its salt as active ingredient. Medication is made in dosed form, which is applied by introduction to patient during treatment in form of eye drops or ophthalmic ointment. ^ EFFECT: invention ensures treatment of such disturbances as dry eye syndrome, ulcer of cornea, keratitis, conjunctivitis, punctuate superficial keratitis, disturbances of corneal epithelium, dry keratoconjunctivitis, upper limbic keratoconjunctivitis or filamentary keratitis. ^ 9 cl, 1 tbl, 2 ex
PURPOSE: Exome or genome sequencing (ES or GS) can identify genetic causes of otherwise unexplained congenital anomaly and perinatal death (PND) but is not routine practice. The evidence base for "genomic autopsy" after termination of pregnancy for fetal anomaly (TOPFA) and PND has been synthesized to determine the value of this investigation.
METHODS: We conducted a systematic review and meta-analysis of studies meeting prespecified inclusion criteria and containing ≥10 cases of TOPFA or PND (with or without major congenital abnormality), in which ES or GS was conducted. We determined test performance, including diagnostic yield, accuracy, and reliability. We also reported outcomes associated with clinical utility and harms, where described.
RESULTS: From 2245 potentially eligible studies, 32 publications were eligible and had data extracted, representing 2120 cases that could be meta-analyzed. No diagnostic accuracy or comparative studies were identified, although some analysis of concordance between different ES/GS methodologies could be performed. Studies reporting parent-related outcomes or long-term follow-up did not do so in a systematic or quantifiable manner.
CONCLUSION: Evidence suggests that approximately one-fourth to one-third of fetal losses associated with TOPFA or unexplained PND are associated with a genetic cause identifiable on ES or GS-albeit this estimate varies depending on phenotypic and background risk factors. Despite the large body of evidence on ES and GS, little research has attempted to validate the accuracy of testing, nor measure the clinical or societal outcomes in families that follow the diagnostic investigation in this context.
Parkinson's disease (PD) is a central nervous system disease with the highest disability and mortality rate worldwide, and it is caused by a variety of factors. The most common medications for PD have side effects with limited therapeutic outcomes. Many studies have reported that chitosan oligosaccharide (COS) crossed blood-brain barrier to achieve a neuroprotective effect in PD. However, the role of COS in PD remains unclear. The present study demonstrated that COS increased dopaminergic neurons in the substantia nigra (SN) and ameliorated dyskinesia in a PD mouse model. Moreover, COS reduced gut microbial diversity and faecal short-chain fatty acids. Valeric acid supplementation enhanced the inflammatory response in the colon and SN, and it reversed COS - suppressed dopamine neurons damage. Autophagy was involved in COS modulating inflammation through valeric acid. These results suggest that COS reduces bacterial metabolites - valeric acid, which diminishes inflammation via activating autophagy, ultimately alleviating PD.
Six subjects will receive a single oral dose of ACT-389949 1 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
For the pseudo-stimulation to be applied to the sham group, the electrodes will be placed on the scalp in exactly the same way as the experimental group. For all stimulations, the reference electrode will be placed in the right orbital region and given once for 15 seconds, so that the participant will feel a slight tingling, but no real stimulation will be given.
Patients will be treated with the normal non-neuronavigated transcranial magnetic stimulation. The treatment protocol is 90%-100% RMT stimulation intensity; 10 Hz frequency for 4 seconds with 26 seconds of rest; 4,000 pulses per session; total duration 50 minutes, twice daily (8,000 pulses/day) for 5 days (40,000 pulses total).
This is a multisite, open-label randomized controlled internal pilot trial designed to assess the feasibility of a larger trial aimed at determining the effectiveness of fecal microbiota transplantation (FMT) by enema in short and long term intestinal decolonization of carbapenemase-producing Enterobacteriaceae (CPE). Forty (40) asymptomatic adult patients intestinally colonized with CPE will be allocated in a 1:1 ratio to receive a bowel preparation followed by FMT by enema route, versus standard of care (no intervention). FMT will be provided by the University of Toronto Microbiota Therapeutics Outcomes Program (MTOP), using standardized operating procedures for recruiting and screening FMT donors, manufacturing FMT and administering FMT by enema. The feasibility outcomes are: successful randomization of 40 patients within 12 months, retention of \>90% (36/40) of patients up to 6 months, and provision of FMT at a non-primary study site in at least one patient. Data on the clinical and exploratory outcomes will be collected but not analyzed in this pilot study. The primary clinical outcome is incidence of intestinal decolonization of CPE at 3 months. Secondary clinical outcomes include: time to decolonization of CPE; incidence of CPE clinical infections up to 12 months post-intervention; incidence of intestinal decolonization of CPE and other antibiotic-resistant organisms (extended spectrum beta-lactamase Enterobacteriaceae - ESBLs and vancomycin-resistant Enterococci - VRE) at 1, 3, 6 and 12 months post-intervention; and, safety profile. As an exploratory outcome, changes in fecal microbiome composition will be examined before and after intervention. This study leverages existing support, research infrastructures and expertise - including the Toronto Invasive Bacterial Diseases Network (TIBDN), Toronto Antimicrobial Resistance Research Network (TARRN), and the University of Toronto Microbiota Therapeutics Outcomes Program (MTOP) - to optimize feasibility regarding patient recruitment and FMT administration.
The vaccine to be investigated is producted in embryonated hen's eggs using an H5N1 reference strain NIBRG-14 which was prepared by NIBSC. The strain is a reassortant between A/Vietnam/1194/2004 and A/PR/8/34 by reverse genetics.

Total 400 volunteers aged from 18 to 60 years old are to be enrolled with 100 subjects in each group. The eligible volunteers will receive two doses vaccine of 5μg，10μg or 15μg haemagglutinin antigen. The schedule is day 0,14 or day 0,28. The subjects will donate their blood samples for the detection of HI antibody and microneutralization antibody. Local and systematic adverse reactions will be recorded during the study.
This form of placebo therapy has been commonly used in prior studies investigating behavioral interventions for insomnia. The therapist presents the QDT as a means to eliminate "conditioned arousal," occurring after nocturnal arousal using 8 sessions on a weekly basis. The therapist initially helps the subject to develop a chronological 12-item hierarchy of commonly practiced activities on awakening at night, like opening eyes and clock watching. As a next step, the subject develops 6 imaginable scenes of himself/herself engaged in neutral activities like reading a newspaper. The therapist then helps the subject pair the neutral scenes with the items from the 12-item hierarchy, which is then practiced by the subject 2 hours before bedtime.
Pain is an hallmark of sickle-cell-related acute clinical manifestations as part of acute vaso-occlusive crisis (VOC). In SCD pain has different origins such as vascular or neuropathic pain, which requires multimodal analgesia. This is based on the administration of drugs with different pharmacological mechanisms of action, maximizing analgesia and minimizing their adverse events and the risk of drug-addition in patients experiencing acute-recurrent pain events as in SCD. Ketorolac is a potent non-narcotic analgesic, being relatively safe and effective during pain-management in children and adults. Up to now, there is a lack of safety information on continuous infusion ketorolac as used to control acute pain in patients with SCD, and the benefits/risks ratio needs to be investigated. Here, we report for the first time the safety profile of ketorolac in the special population of patients with SCD. We confirmed that ketorolac in combination with tramadol, an opioid like molecule, is effective in pain control of adult patients with SCD experiencing acute severe VOCs defined by pain visual analog scale. Our study shows that short term (72 h) continuous infusion of ketorolac plus tramadol is not associated with adverse events such as liver or kidney acute disfunction or abnormalities in coagulation parameters during patients' hospitalization and within 30 days after patients discharge. This is extremely important for patients with SCD, who should have access to multimodal therapy to control recurrent acute pain crisis in order to limit central sensitization a fearsome issue of undertreated recurrent acute pain and of chronic pain.